Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Phase II Clinical Trial of Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study.

NCT02101684 is registered in ClinicalTrials.gov with Grupo Español de Tumores Huérfanos e Infrecuentes as lead sponsor.

NCT NCT02101684
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02101684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Phase II Clinical Trial of Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study.
Lead sponsor
Grupo Español de Tumores Huérfanos e Infrecuentes
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2014
Completion date
January 11, 2017
Enrollment
10 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic or advanced non-resectable granulosa cell ovarian tumors